The respiratory physiome: Clustering based on a comprehensive lung function assessment in patients with COPD

PLoS ONE

Volumn 13, Issue 9, 2018, Pages

  Augustin, Ingrid M L ^a   Spruit, Martijn A ^a,b   Houben Wilke, Sarah ^a   Franssen, Frits M E ^a   Vanfleteren, Lowie E G W ^a   Gaffron, Swetlana ^c   Janssen, Daisy J A ^a   Wouters, Emiel F M ^a,b  

^a CIRO+   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Viscovery Software GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AIRWAY OBSTRUCTION; ARTERIAL GAS; ARTICLE; BODY PLETHYSMOGRAPHY; CARBON MONOXIDE DIFFUSING CAPACITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLUSTER ANALYSIS; COMORBIDITY; DISEASE EXACERBATION; DYSPNEA; EXERCISE; FEMALE; FITNESS; FUNCTIONAL STATUS; HEALTH STATUS; HOSPITALIZATION; HUMAN; HYPERINFLATION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SEX DIFFERENCE; SPIROMETRY; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 85053125171     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0201593     Document Type: Article

References (42)

1. Vogelmeier C.F., et al., Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med, 2017. 195(5): p. 557–582. https://doi.org/10.1164/rccm.201701-0218PP PMID: 28128970
2. Han M.K., et al., Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med, 2010. 182(5): p. 598–604. https://doi.org/10.1164/rccm.200912-1843CC PMID: 20522794
3. Decramer M., et al., Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet, 2009. 374(9696): p. 1171–8. https://doi.org/10.1016/S0140-6736(09)61298-8 PMID: 19716598
4. Wedzicha J.A., et al., Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med, 2013. 1(3): p. 199–209. https://doi.org/10.1016/ S2213-2600(13)70052-3 PMID: 24429126
5. Spruit M.A., et al., Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med, 2010. 104(6): p. 849–57. https://doi.org/10.1016/j.rmed.2009.12.007 PMID: 20471236
6. Agusti A., et al., Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res, 2010. 11: p. 122. https://doi.org/10.1186/1465-9921-11-122 PMID: 20831787
7. Janssen D.J., et al., Symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation. Chron Respir Dis, 2010. 7(3): p. 147–57. https://doi.org/10.1177/1479972310369285 PMID: 20688892
8. Corbridge T. and Irvin C., Pathophysiology of Chronic Obstructive Pulmonary Disease with Emphasis on Physiologic and Pathologic Correlations. In: Casaburi R. and Petty T., Principles and practice of pulmonary rehabilitation. Philadelphia, PA: Saunders, 1993: p. 18–32.
9. O’Donnell D.E., Webb K.A., and Neder J.A., Lung hyperinflation in COPD: applying physilology to clinical practice. COPD Research & Practice, 2015. 1:4: p. 1–12.
10. Marchand E. and Decramer M., Respiratory muscle function and drive in chronic obstructive pulmonary disease. Clin Chest Med, 2000. 21(4): p. 679–92. PMID: 11194779
11. Farkhooy A., et al., Impaired carbon monoxide diffusing capacity is the strongest predictor of exercise intolerance in COPD. COPD, 2013. 10(2): p. 180–5. https://doi.org/10.3109/15412555.2012.734873PMID: 23547629
12. Saure E.W., et al., Diffusion capacity and CT measures of emphysema and airway wall thickness—relation to arterial oxygen tension in COPD patients. Eur Clin Respir J, 2016. 3: p. 29141. https://doi.org/10.3402/ecrj.v3.29141 PMID: 27178139
13. Boutou A.K., et al., Lung function indices for predicting mortality in COPD. Eur Respir J, 2013. 42(3): p. 616–25. https://doi.org/10.1183/09031936.00146012 PMID: 23349449
14. Crisafulli E., et al., Respiratory muscles training in COPD patients. Int J Chron Obstruct Pulmon Dis, 2007. 2(1): p. 19–25. PMID: 18044062
15. Garcia-Aymerich J., et al., Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax, 2011. 66(5): p. 430–7. https://doi.org/10.1136/thx.2010.154484 PMID: 21177668
16. Burgel P.R., Paillasseur J.L., and Roche N., Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. Biomed Res Int, 2014. 2014: p. 420134. https://doi.org/10.1155/2014/420134 PMID: 24683548
17. Esteban C., et al., Chronic Obstructive Pulmonary Disease Subtypes. Transitions over Time. PLoS One, 2016. 11(9): p. e0161710. https://doi.org/10.1371/journal.pone.0161710 PMID: 27611911
18. Smid D.E., et al., Impact of cardiovascular comorbidities on COPD Assessment Test (CAT) and its responsiveness to pulmonary rehabilitation in patients with moderate to very severe COPD: protocol of the Chance study. BMJ Open, 2015. 5(7): p. e007536. https://doi.org/10.1136/bmjopen-2014-007536PMID: 26198426
19. Miller M.R., et al., Standardisation of spirometry. Eur Respir J, 2005. 26(2): p. 319–38. https://doi.org/10.1183/09031936.05.00034805 PMID: 16055882
20. Quanjer P.H., et al., Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J, 2012. 40(6): p. 1324–43. https://doi.org/10.1183/09031936.00080312 PMID: 22743675
21. Coates A.L., et al., Measurement of lung volumes by plethysmography. Eur Respir J, 1997. 10(6): p. 1415–27. PMID: 9192953
22. Quanjer P.H., et al., Lung volumes and forced ventilatory flows. Eur Respir J, 1993. 6 Suppl 16: p. 5–40.
23. Macintyre N., et al., Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J, 2005. 26(4): p. 720–35. https://doi.org/10.1183/09031936.05.00034905 PMID: 16204605
24. Cotes J.E., et al., Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl, 1993. 16: p. 41–52. PMID: 8499053
25. American Thoracic Society/European Respiratory, S., ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med, 2002. 166(4): p. 518–624. https://doi.org/10.1164/rccm.166.4.518PMID: 12186831
26. Black L.F. and Hyatt R.E., Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis, 1969. 99(5): p. 696–702. https://doi.org/10.1164/arrd.1969.99.5.696 PMID: 5772056
27. Charlson M.E., et al., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 1987. 40(5): p. 373–83. PMID: 3558716
28. Mahler D.A. and Wells C.K., Evaluation of clinical methods for rating dyspnea. Chest, 1988. 93(3): p. 580–6. PMID: 3342669
29. Jones P.W., et al., Development and first validation of the COPD Assessment Test. Eur Respir J, 2009. 34(3): p. 648–54. https://doi.org/10.1183/09031936.00102509 PMID: 19720809
30. van der Molen T., et al., Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes, 2003. 1: p. 13. https://doi.org/10.1186/1477-7525-1-13 PMID: 12773199
31. Jones P.W., Quirk F.H., and Baveystock C.M., The St George’s Respiratory Questionnaire. Respir Med, 1991. 85 Suppl B: p. 25–31; discussion 33–7.
32. Zigmond A.S. and Snaith R.P., The hospital anxiety and depression scale. Acta Psychiatr Scand, 1983. 67(6): p. 361–70. PMID: 6880820
33. Schols A.M., et al., Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis, 1993. 147(5): p. 1151–6. https://doi.org/10.1164/ajrccm/147.5.1151 PMID: 8484624
34. Foreman M.G., et al., Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med, 2011. 184(4): p. 414–20. https://doi.org/10.1164/rccm.201011-1928OC PMID: 21562134
35. Pinto L.M., et al., Derivation and validation of clinical phenotypes for COPD: a systematic review. Respir Res, 2015. 16: p. 50. https://doi.org/10.1186/s12931-015-0208-4 PMID: 25928208
36. Vanfleteren L.E., et al., Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2013. 187(7): p. 728–35. https://doi.org/10.1164/rccm.201209-1665OC PMID: 23392440
37. Ziegelstein R.C., Personomics. JAMA Intern Med, 2015. 175(6): p. 888–9. https://doi.org/10.1001/jamainternmed.2015.0861 PMID: 25867929
38. Spruit M.A., et al., An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med, 2013. 188(8): p. e13–64. https://doi.org/10.1164/rccm.201309-1634ST PMID: 24127811
39. Agusti A., et al., Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J, 2016. 47(2): p. 410–9. https://doi.org/10.1183/13993003.01359-2015 PMID: 26828055
40. Ross J.C. and e. al., Longitudinal Modeling of Lung Function Trajectories in Smokers with and without COPD. Am J Respir Crit Care Med, 2018. https://doi.org/10.1164/rccm.201707-1405OC [Epub ahead of print]. PMID: 29671603
41. O’Donnell D.E., Revill S.M., and Webb K.A., Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2001. 164(5): p. 770–7. https://doi.org/10.1164/ajrccm.164.5.2012122 PMID: 11549531
42. Shimizu K., et al., Transfer coefficients (Kco) better reflect emphysematous changes than carbon monoxide diffusing capacity (DLco) in obstructive lung diseases. J Appl Physiol (1985), 2018.